CompletedPhase 1NCT00053144
Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia
Studying Acute erythroid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Roswell Park Cancer Institute
- Principal Investigator
- Maria R. Baer, MDRoswell Park Cancer Institute
- Intervention
- cytarabine(drug)
- Eligibility
- 15 years · All sexes
- Timeline
- 1999 – 2003
Study locations (1)
- Roswell Park Cancer Institute, Buffalo, New York, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00053144 on ClinicalTrials.govOther trials for Acute erythroid leukemia
Additional recruiting or active studies for the same condition.